These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17917142)

  • 1. Psychosocial and behavioral impact of genetic counseling and testing.
    Vadaparampil ST; Miree CA; Wilson C; Jacobsen PB
    Breast Dis; 2006-2007; 27():97-108. PubMed ID: 17917142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial aspects of genetic counseling and testing.
    Vadaparampil ST; Wey JP; Kinney AY
    Semin Oncol Nurs; 2004 Aug; 20(3):186-95. PubMed ID: 15491028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review.
    Pasacreta JV
    Cancer Invest; 2003; 21(4):588-623. PubMed ID: 14533449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
    Kinney AY; Butler KM; Schwartz MD; Mandelblatt JS; Boucher KM; Pappas LM; Gammon A; Kohlmann W; Edwards SL; Stroup AM; Buys SS; Flores KG; Campo RA
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25376862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk.
    Hutson SP
    Oncol Nurs Forum; 2003; 30(2):241-6. PubMed ID: 12692658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
    Halbert CH; Wenzel L; Lerman C; Peshkin BN; Narod S; Marcus A; Corio C; Demarco T; Bellamy S
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):875-81. PubMed ID: 15159322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
    Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
    Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2).
    Juan AS; Wakefield CE; Kasparian NA; Kirk J; Tyler J; Tucker K
    Genet Test; 2008 Dec; 12(4):523-32. PubMed ID: 19072564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
    Schwartz MD; Valdimarsdottir HB; Peshkin BN; Mandelblatt J; Nusbaum R; Huang AT; Chang Y; Graves K; Isaacs C; Wood M; McKinnon W; Garber J; McCormick S; Kinney AY; Luta G; Kelleher S; Leventhal KG; Vegella P; Tong A; King L
    J Clin Oncol; 2014 Mar; 32(7):618-26. PubMed ID: 24449235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 19. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.
    Kelly K; Leventhal H; Andrykowski M; Toppmeyer D; Much J; Dermody J; Marvin M; Baran J; Schwalb M
    J Genet Couns; 2004 Jun; 13(3):237-57. PubMed ID: 15604634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
    Barnes-Kedar IM; Plon SE
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.